has part has role independent continuant dimethyl sulfoxide addition compound antineoplastic agent trametinib dimethyl sulfoxide An addition compound obtained by combining equimolar amounts of trametinib and dimethyl sulfoxide. Used for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, and who have not received prior BRAF inhibitor treatment. CHEBI:75991 trametinib EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor